Full Text of HB3514 102nd General Assembly
HB3514 102ND GENERAL ASSEMBLY |
| | 102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022 HB3514 Introduced 2/22/2021, by Rep. Keith R. Wheeler SYNOPSIS AS INTRODUCED: |
|
720 ILCS 570/210 | from Ch. 56 1/2, par. 1210 |
|
Amends the Illinois Controlled Substances Act. Adds Etizolam and Flualprazolam to the list of Schedule IV controlled substances.
|
| |
| | A BILL FOR |
|
| | | HB3514 | | LRB102 04107 RLC 14124 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 210 as follows:
| 6 | | (720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
| 7 | | Sec. 210.
(a) The controlled substances listed in this | 8 | | Section are
included in Schedule IV.
| 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another schedule,
any material, compound, mixture, or | 11 | | preparation containing limited quantities
of any of the | 12 | | following narcotic drugs, or their salts calculated as the
| 13 | | free anhydrous base or alkaloid, as set forth below:
| 14 | | (1) Not more than 1 milligram of difenoxin (DEA Drug | 15 | | Code No. 9618) and
not less than 25 micrograms of atropine | 16 | | sulfate per dosage unit.
| 17 | | (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
| 18 | | 2-diphenyl-3-methyl-2-propionoxybutane).
| 19 | | (c) Unless specifically excepted or unless listed in | 20 | | another
schedule, any material, compound, mixture, or | 21 | | preparation which contains
any quantity of the following | 22 | | substances having a potential for abuse
associated with a | 23 | | depressant effect on the central nervous system:
|
| | | HB3514 | - 2 - | LRB102 04107 RLC 14124 b |
|
| 1 | | (1) Alprazolam;
| 2 | | (2) Barbital;
| 3 | | (2.1) Bromazepam;
| 4 | | (2.2) Camazepam;
| 5 | | (2.3) Carisoprodol;
| 6 | | (3) Chloral Betaine;
| 7 | | (4) Chloral Hydrate;
| 8 | | (5) Chlordiazepoxide;
| 9 | | (5.1) Clobazam;
| 10 | | (6) Clonazepam;
| 11 | | (7) Clorazepate;
| 12 | | (7.1) Clotiazepam;
| 13 | | (7.2) Cloxazolam;
| 14 | | (7.3) Delorazepam;
| 15 | | (8) Diazepam;
| 16 | | (8.05) Dichloralphenazone;
| 17 | | (8.1) Estazolam;
| 18 | | (9) Ethchlorvynol;
| 19 | | (10) Ethinamate;
| 20 | | (10.1) Ethyl loflazepate;
| 21 | | (10.2) Fludiazepam;
| 22 | |
| 23 | | (10.3) Flunitrazepam;
| 24 | | (11) Flurazepam;
| 25 | | (11.1) Fospropofol;
| 26 | | (12) Halazepam;
|
| | | HB3514 | - 3 - | LRB102 04107 RLC 14124 b |
|
| 1 | | (12.1) Haloxazolam;
| 2 | | (12.2) Ketazolam;
| 3 | | (12.3) Loprazolam;
| 4 | | (13) Lorazepam;
| 5 | | (13.1) Lormetazepam;
| 6 | | (14) Mebutamate;
| 7 | | (14.1) Medazepam;
| 8 | | (15) Meprobamate;
| 9 | | (16) Methohexital;
| 10 | | (17) Methylphenobarbital (Mephobarbital);
| 11 | | (17.1) Midazolam;
| 12 | | (17.2) Nimetazepam;
| 13 | | (17.3) Nitrazepam;
| 14 | | (17.4) Nordiazepam;
| 15 | | (18) Oxazepam;
| 16 | | (18.1) Oxazolam;
| 17 | | (19) Paraldehyde;
| 18 | | (20) Petrichloral;
| 19 | | (21) Phenobarbital;
| 20 | | (21.1) Pinazepam;
| 21 | | (22) Prazepam;
| 22 | | (22.1) Quazepam;
| 23 | | (23) Temazepam;
| 24 | | (23.1) Tetrazepam;
| 25 | | (23.2) Tramadol;
| 26 | | (24) Triazolam;
|
| | | HB3514 | - 4 - | LRB102 04107 RLC 14124 b |
|
| 1 | | (24.5) Zaleplon;
| 2 | | (25) Zolpidem;
| 3 | | (26) Zopiclone. | 4 | | (d) Any material, compound, mixture, or preparation which | 5 | | contains
any quantity of the following substances, including | 6 | | its salts, isomers
(whether optical, position, or geometric), | 7 | | and salts of such isomers,
whenever the existence of such | 8 | | salts, isomers and salts of isomers is
possible:
| 9 | | (1) Fenfluramine.
| 10 | | (e) Unless specifically excepted or unless listed in | 11 | | another
schedule any material, compound, mixture, or | 12 | | preparation which contains
any quantity of the following | 13 | | substances having a stimulant effect on
the central nervous | 14 | | system, including its salts, isomers (whether
optical, | 15 | | position or geometric), and salts of such isomers whenever the
| 16 | | existence of such salts, isomers, and salts of isomers is | 17 | | possible
within the specific chemical designation:
| 18 | | (1) Cathine ((+)-norpseudoephedrine);
| 19 | | (1.1) Diethylpropion;
| 20 | | (1.2) Fencamfamin;
| 21 | | (1.3) Fenproporex;
| 22 | | (2) Mazindol;
| 23 | | (2.1) Mefenorex;
| 24 | | (3) Phentermine;
| 25 | | (4) Pemoline (including organometallic complexes and | 26 | | chelates
thereof);
|
| | | HB3514 | - 5 - | LRB102 04107 RLC 14124 b |
|
| 1 | | (5) Pipradrol;
| 2 | | (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);
| 3 | | (7) Modafinil;
| 4 | | (8) Sibutramine.
| 5 | | (f) Other Substances. Unless specifically excepted or | 6 | | unless listed in
another schedule, any material,
compound,
| 7 | | mixture, or preparation that contains any quantity of the | 8 | | following substance,
including its
salts:
| 9 | | (1) Butorphanol (including its optical isomers) ; .
| 10 | | (2) Etizolam; | 11 | | (3) Flualprazolam. | 12 | | (g) The Department may except by rule any compound, | 13 | | mixture, or
preparation containing any depressant substance | 14 | | listed in subsection (b)
from the application of all or any | 15 | | part of this Act if the compound,
mixture, or preparation | 16 | | contains one or more active medicinal
ingredients not having a | 17 | | depressant effect on the central nervous
system, and if the | 18 | | admixtures are included therein in combinations,
quantity, | 19 | | proportion, or concentration that vitiate the potential for
| 20 | | abuse of the substances which have a depressant effect on the | 21 | | central
nervous system.
| 22 | | (h) Except as otherwise provided in Section 216, any | 23 | | material, compound,
mixture, or preparation that contains any
| 24 | | quantity of the following substance having a stimulant effect | 25 | | on the central
nervous system, including its salts, | 26 | | enantiomers (optical isomers) and salts of
enantiomers |
| | | HB3514 | - 6 - | LRB102 04107 RLC 14124 b |
|
| 1 | | (optical isomers):
| 2 | | (1) Ephedrine, its salts, optical isomers and salts of | 3 | | optical isomers.
| 4 | | (Source: P.A. 97-334, eff. 1-1-12.)
|
|